These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

996 related items for PubMed ID: 17505496

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM, Tufail W, Hutchinson J, Tenorio J, Baliga MP.
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [Abstract] [Full Text] [Related]

  • 5. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    Ross JS, Ginsburg GS.
    Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
    [Abstract] [Full Text] [Related]

  • 6. The current status and future potential of personalized diagnostics: Streamlining a customized process.
    Richmond TD.
    Biotechnol Annu Rev; 2008 Jan; 14():411-22. PubMed ID: 18606372
    [Abstract] [Full Text] [Related]

  • 7. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
    Issa AM.
    Adv Health Econ Health Serv Res; 2008 Jan; 19():191-206. PubMed ID: 19548519
    [Abstract] [Full Text] [Related]

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE, Kleijnen J.
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Companion diagnostics: significances and issues in its clinical application].
    Miyachi H.
    Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
    [Abstract] [Full Text] [Related]

  • 14. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J, Puech A, Boissel JP, Participants inRound Table No 7, Giens XXII.
    Therapie; 2007 Jun; 62(5):427-35. PubMed ID: 18206104
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The prospects for "personalized medicine" in drug development and drug therapy.
    Woodcock J.
    Clin Pharmacol Ther; 2007 Feb; 81(2):164-9. PubMed ID: 17259943
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Affymetrix DMET platform and pharmacogenetics in drug development.
    Deeken J.
    Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.